Asia FX rises; US-Japan trade deal boosts yen, won to 2-week highs
Cardinal Health Inc. (NYSE:CAH) stock reached an all-time high of 166.3 USD, marking a significant milestone for the company. According to InvestingPro data, the company maintains a healthy dividend track record, having paid dividends for 43 consecutive years, with a current yield of 1.24%. Over the past year, Cardinal Health has seen its stock price increase by an impressive 61.3%, reflecting strong investor confidence and robust business performance. The company’s management has been actively buying back shares, while 12 analysts have recently revised their earnings expectations upward. The healthcare services and products company has been on an upward trajectory, driven by strategic initiatives and a focus on innovation. This latest achievement underscores Cardinal Health’s position in the market, as it continues to expand its footprint and enhance shareholder value. InvestingPro analysis suggests the stock currently trades above its Fair Value, with 16 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Cardinal Health has raised its full-year profit forecast, surpassing analyst expectations. The company now anticipates adjusted earnings per share (EPS) of $8.15 to $8.20 for the current fiscal year, exceeding the previous guidance of $8.05 to $8.15. This new forecast is above the average analyst estimate of $8.14. UBS and Jefferies have both raised their price targets for Cardinal Health, with UBS increasing it to $185 and Jefferies to $190, while maintaining Buy ratings. Cardinal Health also established preliminary guidance for fiscal year 2026, projecting adjusted EPS of $9.10 to $9.30, indicating a 13% growth at the midpoint. The company confirmed its long-term target of a 12% to 14% compound annual growth rate for adjusted EPS from fiscal years 2026 through 2028. Additionally, Cardinal Health plans to generate at least $10 billion in total adjusted free cash flow over the next three years and has increased its baseline share repurchase plans to at least $750 million per year. The company announced several strategic initiatives, including the launch of The Specialty Alliance platform and investments in its Nuclear and Precision Health Solutions business.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.